Auranofin is an effective agent against clinical isolates of Staphylococcus aureus

Página do item simplificado
dc.contributor.authorTharmalingam, Nagendran
dc.contributor.authorRibeiro, Noelly Q.
dc.contributor.authorDa Silva, Danielle L.
dc.contributor.authorNaik, Mandar T.
dc.contributor.authorCruz, Lana I.B.
dc.contributor.authorKim, Wooseong
dc.contributor.authorShen, Steven
dc.contributor.authorDos Santos, Jéssica D. [UNESP]
dc.contributor.authorEzikovich, Katarina
dc.contributor.authorD'Agata, Erika M.C.
dc.contributor.authorMylonakis, Eleftherios
dc.contributor.authorFuchs, Beth B.
dc.contributor.institutionAlpert Medical School and Brown University
dc.contributor.institutionUniversidade Federal de Minas Gerais (UFMG)
dc.contributor.institutionBrown University
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2019-10-06T16:42:35Z
dc.date.available2019-10-06T16:42:35Z
dc.date.issued2019-01-01
dc.description.abstractAim: The orphan drug auranofin was recently found to exhibit antimicrobial properties. Materials & methods: We explored the efficacy of auranofin by evaluating the minimal inhibitory concentration against a collection of over 500 clinical isolates derived from multiple institutions, inclusive of drug resistant strains. Our evaluation also included continuous exposure of bacteria to auranofin. Results & conclusion: We found that minimal inhibitory concentrations ranged between 0.125 and 1 mg/l, exerting robust antimicrobial activity against a sizeable clinical collection of the bacteria. Further, we evaluated the propensity of the methicillin-resistant Staphylococcus aureus strain MW2 to develop resistance through extended exposure to auranofin. After 25 days, the bacteria remained susceptible. Our data suggest that resistance mechanisms do not currently exist to block auranofin antimicrobial activity.en
dc.description.affiliationDepartment of Medicine Division of Infectious Diseases Rhode Island Hospital Alpert Medical School and Brown University
dc.description.affiliationDepartment of Microbiology Instituto de Ciências Biológicas Universidade Federal de Minas Gerais
dc.description.affiliationDepartment of Molecular Pharmacology Physiology and Biotechnology Brown University
dc.description.affiliationDepartment of Biosciences and Oral Diagnosis Universidade Estadual Paulista UNESP São José Dos Campos
dc.description.affiliationUnespDepartment of Biosciences and Oral Diagnosis Universidade Estadual Paulista UNESP São José Dos Campos
dc.description.sponsorshipNational Institute of Allergy and Infectious Diseases
dc.description.sponsorshipIdNational Institute of Allergy and Infectious Diseases: K24 AI119158
dc.format.extent1417-1425
dc.identifierhttp://dx.doi.org/10.4155/fmc-2018-0544
dc.identifier.citationFuture Medicinal Chemistry, v. 11, n. 12, p. 1417-1425, 2019.
dc.identifier.doi10.4155/fmc-2018-0544
dc.identifier.issn1756-8927
dc.identifier.issn1756-8919
dc.identifier.scopus2-s2.0-85070402920
dc.identifier.urihttp://hdl.handle.net/11449/189497
dc.language.isoeng
dc.relation.ispartofFuture Medicinal Chemistry
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectantimicrobial
dc.subjectauranofin
dc.subjectdrug-resistant bacteria
dc.subjectMRSA
dc.subjectStaphylococcus aureus
dc.subjectthioredoxin reductase
dc.subjectVISA
dc.titleAuranofin is an effective agent against clinical isolates of Staphylococcus aureusen
dc.typeArtigo

Arquivos

Coleções

Artigos - Biociências e Diagnóstico Bucal - ICT